With the expansion of Oncology and Immuno-Oncology drug development, effective preclinical platforms are required for testing efficacy and safety of new targets. Matching a promising target to the best patient population requires an arsenal of tools, in depth expertise, and models that reflect the patient clinical situation as early as the in vitro stage of preclinical drug development.
In vitro technologies, especially within the Organoid space are revolutionizing Oncology Drug Discovery and Development. While there have been great advances there are still hurdles to overcome. Discover what is next for this innovative and disruptive technology and understand the key differences between 3D in vitro systems, such as cell lines and patient-derived models including organoids.
This symposium will bring together R&D and preclinical teams from pharmaceutical and biotech companies to facilitate cross-discipline discussions on current techniques and the application of future approaches. Learn how to select the right 3D in vitro platform for your drug development program based on model features, benefits, and limitations.
Join us for a full agenda of talks from the leading researchers in this rapidly developing area, followed by an opportunity to network with your peers at a complimentary drink’s reception
Attendance for the symposium is free but space is limited. We encourage early registration.
Lunch will be served.